Recent studies have shown that 3-bromopyruvate, a hexokinase 2 (HK2) inhibitor, and its derivatives (pentyl 3-bromopyruvate ester [P-BrPE] and 3-bromo-2-oxopropionate-1-propyl ester [3-BrOP]) reduce the viability of CSCs and that knockdown of GLUT3 inhibits the growth of brain tumor CSCs [23, 25-28]. This evidence concerns the gene SLC2A3 and brain neoplasm.